| abstract |
The invention discloses a chimeric molecule. The molecule is composed of a small molecular compound unit targeting the target protein, an E3 ubiquitin ligase binding unit and a linking unit. The compound can be combined with the BRD protein, and finally make the BRD protein easy to be degraded by the proteasome, and can be used as a drug for the degradation of the BRD protein to treat cancer or coronary artery disease. |